Drug Profile
Defactinib companion diagnostic - Verastem Oncology/LabCorp
Alternative Names: Defactinib companion diagnostic; VS-6063 companion diagnosticLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Laboratory Corporation of America Holdings; Verastem
- Developer Laboratory Corporation of America Holdings; Verastem Oncology
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mesothelioma
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Mesothelioma(Diagnosis) in USA
- 03 May 2018 Verastem is now operating as Verastem Oncology
- 10 Jan 2013 Verastem and Laboratory Corporation of America Holding are collaborating to develop a companion diagnostic for defactinib